Publications database

The EMCDDA–Europol Joint Report on new psychoactive substance MDPV (3,4-methylenedioxypyrovalerone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the available evidence, the...

The EMCDDA–Europol Joint Report on new psychoactive substance methoxetamine (2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the available evidence, the...

The EMCDDA–Europol Joint Report on new psychoactive substance AH-7921 (3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the available evidence, the...

Concerns about the availability and use of methamphetamine in Europe have been growing for some time. Historically, the use of methamphetamine has been confined largely to the Czech Republic and Slovakia; however...

This report presents the data and findings of the risk assessment on the new psychoactive substance, 4-methylamphetamine, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and...

This report presents the data and findings of the risk assessment on the new psychoactive substance, 5-(2-aminopropyl)indole (5-IT), that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability...

This study explores the civil society organisations that engage in drug policy advocacy in Europe. An Internet search in English, French and Spanish combined with information from national sources in 30 countries...

Drug law enforcement activity targets the supply of drugs and is responsible for much of the key data that informs our understanding of drugs supply in Europe. This study looks, for the...

The production and trafficking of illicit drugs poses complex and interlinked problems, which have a negative impact on public health and the security and stability of society. Focusing on actions directed at...

In this issue: New-style EMCDDA expert meetings promote integrated approach to monitoring | Harm reduction in Europe 2003–13 | European Commission calls for stronger EU action on new drugs | EMCDDA: 20...